The second quarter of 2021 was another record-breaking period for the synthetic biology startup community. Building on the extremely high amount of investment we saw in Q1 ($4.7 billion), Q2 also brought in more than $4.2 billion in venture funding to synthetic biology startups.
The amount of money raised by synthetic biology startups in the second quarter proved that the remarkable performance in Q1 wasn’t a one-time fluke. On the contrary, the money was spread widely over nearly every dimension, from synbio stack to stage of investment, company size, application, and geography.
For further information, please see the complete report from industry-leading analyst Mark Bünger:2